CandlesenseCandlesense
CSTLClinical Trials•globenewswire•

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Sentiment:Positive (72)

Summary

Castle announced the publication of two new studies related to its DecisionDx-SCC test for patients with high-risk cutaneous squamous cell carcinoma.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 25, 2025 by globenewswire

← Back to CSTL News
    New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma | CSTL Stock News | Candlesense